Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Azmeraw M, Workineh Y, Girma F, Kassaw A, Kerebeh G, et al.
…rtant to maintain children's initial antiretroviral therapy regimens. However, the incidence and predictive factors of initial antiretroviral therapy regimen changes in the research context are still unknown in the study setting. So, the study was aimed to assess incidence and pr…
Kohler S, Sitali N, Achar J, Paul N
…hs), 10 shorter (9-12 months), and 8 short (≤6 months) drug regimens for drug-sensitive (DS) and multidrug-resistant (MDR)-TB treatment. Costs per regimen were estimated by multiplying recommended drug amounts with 2021 Global Drug Facility prices and drug import costs of a TB pr…
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, et al.
…idrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. Methods We conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluo…
Stagg HR, Thompson JA, Lipman MCI, Sloan DJ, Flook M, et al.
… nonadherence occurs on the forgiveness of antituberculosis regimens. Methods: Using data from three randomized controlled trials comparing experimental 4-month regimens for drug-sensitive tuberculosis with the standard 6-month regimen, we used generalized linear models to examin…
Marcela Muñoz-Torrico, Rafael Laniado-Laborín, Jorge Rojas-Serrano, Eduardo Becerril-Vargas, Wendy Cinecio-Chávez, et al.
…ere mainly related to linezolid use. **CONCLUSIONS:** Oral regimens appear to be effective, although toxicity to linezolid requires strict patient monitoring.
Velayutham B, Jawahar MS, Nair D, Navaneethapandian P, Ponnuraja C, et al.
…iority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India. Methods New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month…
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, et al.
…EAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen. Methods We did a randomised, phase 3, non-inferiority trial in 13 hospital clinics in seven countries, in individuals aged 15 years or older with rifampicin-resistant tub…
Nicholas I Paton, Christopher Cousins, Intan P Sari, Erlina Burhan, Nan-Kai Ng, et al.
…D:** WHO recommends a 2-month optimal duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial. **METHODS…
Vesga JF, Lienhardt C, Nsengiyumva P, Campbell JR, Oxlade O, et al.
…en important improvements in available preventive treatment regimens for tuberculosis (TB), and research is ongoing to develop these further. To assist with the formulation of target product profiles for future regimens, we examined which regimen properties would be most influent…
Liu Y, Pertinez H, Davies GR, Gillespie SH, Coates AR, et al.
…oxifloxacin for isoniazid or ethambutol in standard anti-TB regimens reduces the treatment duration and relapse rates in animal studies, and 4-month regimens were not noninferior in clinical trials. Resuscitation-promoting factor (RPF)-dependent bacilli have recently been implica…
Gupta A, Juneja S, Babawale V, Rustam Majidovich N, Ndjeka N, et al.
…e rollout of new WHO-recommended shorter all-oral treatment regimens for drug-resistant TB (DR-TB), which remains a public-health crisis. The all-oral, 6-month BPaL/M regimen comprises 3-4 drugs: pretomanid used in combination with bedaquiline and linezolid, with or without moxif…
Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, et al.
…tent to which future improvements in tuberculosis treatment regimens could offset potential increases in drug costs. Methods In this modelling analysis, we used an ingredients-based approach to estimate prices at which novel regimens for rifampin-susceptible and rifampin-resistan…
Malaisamy Muniyandi, Balaji Ramraj, Sathishkumar Vadamalai, Sahil Abdul Salam, Bella Devaleenal, et al.
**BACKGROUND:** Short-course regimens are currently explored to improve multidrug-resistant tuberculosis effects, reduce costs, as well as enhance patient adherence. Currently, we are determining the most cost-effective shorter regimen out of seven short-course regimens (6-9 …
Kohler S, Sitali N, Achar J, Paul N
…nd their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the costs for purchasing and importing TB drugs. Methods We estimated the drug costs and import costs of 39 longer and shorter TB drug regimen…
Muniyandi M, Ramesh PM, Wells WA, Alavadi U, Sahu S, et al.
Objective To measure the economic impacts of the longer pre-XDR-TB treatment regimen and the shorter BEAT-TB India regimen. Methods In the current study, the economic impacts of the current 18-month pre-XDR-TB treatment regimen and the 6-9 month BEAT-TB regimen were evaluated usi…
Norbert Ndjeka, Rubeshan Perumal, Kamila Romanowski, Hlengani Mathema, Lateef Babatunde Amusa, et al.
**BACKGROUND:** Shorter all-oral regimens for the treatment of multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) have improved efficacy, but their performance under programmatic conditions remains insufficiently characterized. **METHODS:** We retr…
Vijay Kumar, G S Sri Bharathi, Mohit Bhatia, Sankha Shubhra Chakrabarti, Upinder Kaur, et al.
…nalyze therapeutic outcomes with bedaquiline-based all-oral regimens for drug-resistant tuberculosis. A prospective observational study was conducted from August 2022 to March 2024 and patients of drug-resistant tuberculosis on all-oral regimens were enrolled. Among 100 patients …
Khan PY, Franke MF, Hewison C, Seung KJ, Huerga H, et al.
…le agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the injectable agent, particularly in the context of regimens using new and repurposed drugs. We compared the effectiveness of an injectable-containing regimen to tha…
Adriana Chacón, Yamile Celis Bustos, Dany Martinez, Felix Chong, Clara Freile, et al.
…ogrammatic cohort, the nine-month all-oral shorter and BPaL regimens were associated with favorable treatment outcomes, acceptable safety profiles, improved adherence, and reduced loss to follow-up compared with injectable-based therapy. These findings supported Ecuador’s …
Nguyen TMP, Nguyen BH, Hoang TTT, Nguyen HA, Vu DH, et al.
…on (WHO) recently recommended standardized all-oral shorter regimens for rifampicin resistant Tuberculosis (RR-TB). For highly resistant Tuberculosis patients such as pre-XDR-TB: RR-TB plus additional resistance to fluoroquinolones (FQ), the 6-9-months bedaquiline (bedaquiline)-b…
Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, et al.
…ared the cost-effectiveness of bedaquiline (BDQ) containing regimens with injectable containing regimens (short-course regimen [SCR] and long-course regiman [LCR]) in India, Russia, and South Africa. Methods The analysis evaluated the direct costs of DR-TB treatment which include…
Shabadi N, Prashanth Kumar NK, Prakash B, Kulkarni P, Narayana Murthy MR
Introduction In the context of changing over from an intermittent treatment regimen to a daily regimen, it becomes crucial to understand the impact of a daily regimen on the treatment process and outcome. It enables health professionals to strengthen strategies, to enhance the qu…
Yilin Zhang, Yang Li, Yan Ren, Ting Li, Yajiao Xing, et al.
…great threat to global health. Increasing evidence of novel regimens in trial settings has risen, but the combinations of oral shorter regimens have not been optimised. An evaluation of the efficacy and safety of short-term regimens utilizing various drug combinations is essentia…
Xinxin Zeng, Hao Xu, Aole Li, Juanjuan Liu, Yuhang Wu, et al.
…for childhood tuberculosis (TB), evaluation of TB treatment regimens for children in real-world settings in China remained limited, particularly regarding treatment duration, utilization of second-line anti-TB drugs (SLDs), and adverse events. This study aimed to describe the tre…
Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.
…cal considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without a fourth drug, have been shown to be as or more effective than the established longer regimens for t…